Related Experiment Video
Updated: Mar 18, 2026
Electrophysiological Measurements and Analysis of Nociception in Human Infants
Published on: December 20, 2011
Clinical pharmacology of analgosedatives in neonates: ways to improve their safe and effective use
Anne Smits1,2, John N van den Anker3,4,5,6, Karel Allegaert3,7
1Neonatal Intensive Care Unit, VU Medical Center, Amsterdam, The Netherlands.
Insights
Structured product development programs are essential for the safe and effective use of neonatal analgosedatives. Tailored approaches, including long-term safety and pharmacogenetics, are crucial for optimizing pain management in fragile infants.
Area of Science:
- Neonatal pharmacology
- Drug development
- Pediatric critical care
Background:
- Neonates require specialized approaches for safe and effective analgosedative use.
- Current practices necessitate tailored drug development programs for this vulnerable population.
Purpose of the Study:
- To propose structured product development programs for neonatal analgosedatives.
- To enhance the safe and effective administration of these agents in neonates.
Main Methods:
- Illustrating feasibility with morphine development programs.
- Developing tailored pharmacodynamic tools for short-acting agents like propofol.
- Focusing on long-term safety for drugs like paracetamol.
Main Results:
- Structured development programs are feasible and relevant for neonatal analgosedatives.
- Individualized dosing, long-term safety, and pharmacogenetics are key components.
- Pharmacodynamic tools and integration of covariates like age, weight, and pharmacogenetics are critical.
Conclusions:
- Product development programs for neonatal analgosedatives are necessary.
- These programs must be tailored to neonatal needs, including short-acting sedation and pain relief.
- Incorporating long-term safety and exploring novel covariates like pharmacogenetics are vital.
Objectives:
To propose approaches tailored to the specific needs of neonates, such as structured product development programmes, with the ultimate goal to improve the safe and effective use of analgosedatives in these fragile patients.
Key Findings:
The feasibility and relevance of a structured product development programme in neonates (optimal study design based on preliminary data; model development; internal, external and prospective evaluation; an individualized dosing regimen; long-term safety; pharmacogenetics) are illustrated for the use of morphine. Based on changes in clinical practices, similar development plans are in progress for short-acting analgosedatives such as propofol, but are in need of tailored pharmacodynamic tools to assess and quantify effects. Furthermore, for drugs like paracetamol where there is already sufficient clinical pharmacology knowledge, attention needs to be given to long-term safety aspects. Finally, new covariates such as pharmacogenetics might further improve neonatal pain management, but clearly need to be integrated with other well-established covariates like age or weight.
Summary:
Product development programmes for analgosedatives in neonates are needed. These programmes should be tailored to their specific needs (short-acting sedation, pain relief), should include long-term safety and should incorporate the exploration of newer covariates like pharmacogenetics.
Related Concept Videos
01:24Parenteral Anesthetics: Overview
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
01:23Sedatives and Hypnotics: Overview
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
01:25Analgesia and Pain Management
01:20Sedatives and Hypnotics Drugs: Barbiturates
01:15Opioid Analgesics: Synthetic and Semisynthetic Opioids